GILEAD SCIENCES SL
🇪🇸Spain
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.
- First Posted Date
- 2006-03-02
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 112
- Registration Number
- NCT00298363
- Locations
- 🇵🇱
Wojewodzki Szpital Zakazny, Warsaw, Poland
🇪🇸Hospital Clinic i Provincial de Barcelona (HCPB), Barcelona, Spain
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-02-02
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 82
- Registration Number
- NCT00285428
- Locations
- 🇺🇸
New York Presbyterian Hospital/Cornell Medical Center, New York, New York, United States
🇺🇸University Hospital of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-12-28
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT00270556
Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.
Completed
- Conditions
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2009-02-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT00263614
- Locations
- 🇺🇸
Gilead Sciences, Inc., Foster City, California, United States
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT00224445
- Locations
- 🇺🇸
Gilead Sciences, Inc., Foster City, California, United States
Combination of Efavirenz and Truvada - COMET Study
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT00224458
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1231
- Registration Number
- NCT00208299
- Locations
- 🇺🇸
Multiple study locations (see Central Contact); CV Therapeutics, Inc., Palo Alto, California, United States
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 787
- Registration Number
- NCT00208312
- Locations
- 🇺🇸
Multiple study locations (see Central Contact); CV Therapeutics, Inc., Palo Alto, California, United States
Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 180
- Registration Number
- NCT00158821
Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.
Not Applicable
Terminated
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-03-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT00158704
© Copyright 2024. All Rights Reserved by MedPath